Featured Research

from universities, journals, and other organizations

Combination Treatment Shows Promise For Schizophrenia

Date:
December 26, 2002
Source:
Department Of Veterans Affairs
Summary:
Reporting in the January issue of the journal Neuropsychopharmacology, Portland Veterans Affairs Medical Center researchers and colleagues have found that combining the anticonvulsant drug divalproex with either olanzapine or risperidone-two commonly used antipsychotic drugs-significantly enhanced and hastened responses in patients suffering from acute psychotic episodes of schizophrenia.

PORTLAND, Oregon, December 20, 2002 -- Reporting in the January issue of the journal Neuropsychopharmacology, Portland Veterans Affairs Medical Center researchers and colleagues have found that combining the anticonvulsant drug divalproex with either olanzapine or risperidone-two commonly used antipsychotic drugs-significantly enhanced and hastened responses in patients suffering from acute psychotic episodes of schizophrenia.

"Our findings suggest that combination therapy with divalproex can decrease the mental pain and suffering for many patients with schizophrenia and shorten the time they need to be in the hospital," said study leader Daniel E. Casey, M.D., Associate Director of Research for the VA Northwest Network's Mental Illness Research, Education and Clinical Center, Chief of Psychiatric Research at the Portland VAMC and Professor of Psychiatry and Neurology at Oregon Health & Science University.

Compared to patients treated with either antipsychotic drug alone, the researchers found, those treated with the combination showed an enhanced reduction of symptoms as early as the third day of therapy. Further, the combination therapy was as well tolerated as either antipsychotic drug used alone, with no additional side effects.

More than 2 million Americans suffer from schizophrenia. One of the world's most common and potentially devastating of all mental illnesses, this chronic disorder is characterized by symptoms such as delusions, hallucinations and grossly disorganized behavior. Patients often have difficulty recognizing reality, thinking logically and behaving normally in social situations. Antipsychotic medications can help many schizophrenia patients lead normal lives, Casey pointed out, but the disorder's causes are incompletely understood and there is no cure.

Although divalproex is commonly used to treat mood disorders, seizures and migraine headache, scientists long ago found the drug ineffective if used alone to treat schizophrenia. Since about 10 percent of patients suffering from schizophrenia also have mood-disorder symptoms, however, divalproex is often used in combination with antipsychotics that target the schizophrenia symptoms.

"We've been getting a clinical signal from physicians that patients receiving this combination seem to improve more in their schizophrenia symptoms than those being treated with an antipsychotic alone," Casey said. "We needed to find out if this signal pointed to something real." The resultant study is the first large-scale trial to assess divalproex in combination with an antipsychotic agent in the treatment of schizophrenia.

In their multi-center trial, Casey and his colleagues studied 249 patients between ages 18-65 who were hospitalized with an acute psychotic episode (exacerbation) of schizophrenia. Patients who also suffered from mood symptoms were excluded from the trial. Sixty-five participants were randomly assigned to receive the antipsychotic olanzapine, 66 received olanzapine with divalproex, 60 received the antipsychotic risperidone alone and 58 got risperidone plus divalproex.

Olanzapine and risperidone belong to two different classes of antipsychotic drugs, Casey noted. Patients were treated for 28 days and evaluated at 3, 5, 7, 10, 14, 21 and 28 days with the Positive and Negative Syndrome Scale total score, a common psychiatric diagnostic tool used to measure changes in patient behavior. Improvements from baseline scores were observed throughout the treatment period in all four groups.

"At day 3 we were already seeing significant enhancement of benefits in the combination groups," Casey said. Clinical improvement, defined as a 20 percent or greater improvement from baseline scores, was seen in 53 percent of patients in the combination groups on day 7, but this degree of improvement was not achieved until day 14 in the groups being treated by either antipsychotic drug alone. A 20 percent improvement in symptoms is commonly used as a threshold to determine that a patient is ready to leave the hospital, Casey pointed out, "so for many patients the combination therapy has the potential to cut in half the time they have to spend in the hospital."

Both combination and single-drug therapy were well tolerated. Adverse effects and rates of discontinued therapy were similar among all treatment groups.

About 25-30 percent of schizophrenia patients respond poorly to antipsychotic drug therapy, Casey noted. Potential results of longer combination therapy in these patients remains to be explored, he said, as well as whether the enhanced improvements of combination therapy observed in this study will be sustained, increased or diminished over longer periods of follow-up.

In addition to Casey, the research team included David G. Daniel, M.D., of George Washington University and Bioniche Development; Adel Wassef, M.D., of the University of Texas, Houston; Katherine Tracy, M.D., Ph.D., of the University of Illinois, Chicago, and Abbott Laboratories; and Patricia Wozniak, Ph.D., and Kenneth W. Sommerville, M.D., of Abbott Laboratories, as well as many other investigators in the divalproex study group. The research was supported in part by Abbott Laboratories.


Story Source:

The above story is based on materials provided by Department Of Veterans Affairs. Note: Materials may be edited for content and length.


Cite This Page:

Department Of Veterans Affairs. "Combination Treatment Shows Promise For Schizophrenia." ScienceDaily. ScienceDaily, 26 December 2002. <www.sciencedaily.com/releases/2002/12/021226071314.htm>.
Department Of Veterans Affairs. (2002, December 26). Combination Treatment Shows Promise For Schizophrenia. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2002/12/021226071314.htm
Department Of Veterans Affairs. "Combination Treatment Shows Promise For Schizophrenia." ScienceDaily. www.sciencedaily.com/releases/2002/12/021226071314.htm (accessed July 23, 2014).

Share This




More Mind & Brain News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Idaho Boy Helps Brother With Disabilities Complete Triathlon

Idaho Boy Helps Brother With Disabilities Complete Triathlon

Newsy (July 23, 2014) An 8-year-old boy helped his younger brother, who has a rare genetic condition that's confined him to a wheelchair, finish a triathlon. Video provided by Newsy
Powered by NewsLook.com
Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Newsy (July 22, 2014) The 83 new genetic markers could open dozens of new avenues for schizophrenia treatment research. Video provided by Newsy
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Do Obese Women Have 'Food Learning Impairment'?

Do Obese Women Have 'Food Learning Impairment'?

Newsy (July 18, 2014) Yale researchers tested 135 men and women, and it was only obese women who were deemed to have "impaired associative learning." Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins